Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009991 | 0.85 | PTGDR2 (0.49) | HDAC1HDAC8HDAC6KMOKCNK2 | |
| SCHEMBL23631635 | 0.85 | HDAC1 (0.46) | HDAC1HDAC8HDAC6RAB9APDE5A | |
| SCHEMBL659925 | 0.84 | KDM4E (0.47) | KDM4EHDAC1HDAC8HDAC6NPY5R | |
| SCHEMBL27633504 | 0.84 | USP2 (0.49) | KDM4EALDH1A1SMN1; SMN2NPSR1TP53 | |
| SCHEMBL29725710 | 0.84 | USP2 (0.49) | KDM4EALDH1A1SMN1; SMN2NPSR1TP53 | |
| SCHEMBL12471781 | 0.83 | PLK1 (0.46) | KDM4EHDAC1HDAC8HDAC6NPY5R | |
| SCHEMBL662079 | 0.83 | TP53 (0.51) | KDM4EHDAC1HDAC8HDAC6NPY5R | |
| SCHEMBL662880 | 0.82 | MAPT (0.54) | KDM4EHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL30361168 | 0.82 | MAPT (0.54) | KDM4EHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL663177 | 0.81 | THRB (0.46) | KDM4ENPY5RRAB9ATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | claimed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2022-07-14 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| US-10806717-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180125818-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| EP-2533645-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160038463-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2016-02-11 | — | — | US | disclosed |
| US-20150094352-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2014-07-24 | — | — | US | disclosed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100099735-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-04-22 | — | — | US | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| EP-1620399-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004087658-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806717-B2 | Methods and compositions for improving cognitive function | GRIN2A, CHRNA2, SYNGR2 | KDM4E 1177/4885HDAC1 826/4885HDAC8 605/4885 |
| US-20160038463-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | KDM4E 1177/4885HDAC1 826/4885HDAC8 605/4885 |
| US-20150094352-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | KDM4E 802/4885HDAC1 4215/4885HDAC8 2682/4885 |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | KDM4E 1177/4885HDAC1 826/4885HDAC8 605/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | KDM4E 3701/4885HDAC1 790/4885HDAC8 577/4885 |
| US-20100099735-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | KDM4E 802/4885HDAC1 4215/4885HDAC8 2682/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | KDM4E 3495/4885HDAC1 1910/4885HDAC8 2683/4885 |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | KDM4E 2148/4885HDAC1 2228/4885HDAC8 2996/4885 |
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | KDM4E 2148/4885HDAC1 2228/4885HDAC8 2996/4885 |
| US-20180125818-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | KDM4E 2148/4885HDAC1 2228/4885HDAC8 2996/4885 |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | KDM4E 1236/4885HDAC1 554/4885HDAC8 381/4885 |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | KDM4E 802/4885HDAC1 4215/4885HDAC8 2682/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | KDM4E 1177/4885HDAC1 826/4885HDAC8 605/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | KDM4E 3554/4885HDAC1 912/4885HDAC8 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.